Skip to Content

AstraZeneca PLC AZN

Rating as of

Morningstar’s Analysis

Valuation
Currency in GBX
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Likely Democrat Senate Control Ups Potential for New Drug Policies, but Major Changes Look Unlikely

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

With the Democrats being very close to winning the remaining two Senate seats in the Georgia runoffs, we expect the Biden administration will seek to implement further healthcare reforms. However, with such a slim possible majority in the Senate, we expect significant compromises that will likely lead to watered-down drug policy changes. We continue to view the biopharma group as undervalued with strong underlying fundamentals, but we expect lingering concern about drug policy changes to weigh on the industry's valuations. 

Read Full Analysis

Company Profile

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Contact
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom
T +44 2037495000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 70,600

Related